Current Report Filing (8-k)
14 Mayo 2021 - 8:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): May 12, 2021
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-56035
|
46-2316220
|
(State
or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification No.)
|
|
1402 N. El
Camino Real
San
Clemente, CA
|
92672
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code (714) 392-9752
N/A
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section
1 - Registrant’s Business and Operations
Item
1.01 Entry into a Material Definitive Agreement.
On
May 12, 2021, Global Wholehealth Partners Corporation (the “Company”) executed an Agreement with Dr. AnhDao Vu Le
(“Dr. Le”) dated January 12, 2021. The delay in executing the Agreement was a direct result of the COVID 19 pandemic.
Under the terms of the Agreement, the Company has engaged Dr. Le to serve as medical director of the CLIA labs. This Agreement will
allow the Company to open
up a CLIA WAIVED LAB and do mobile COVID 19 testing and other CLIA WAIVED tests. The foregoing description of the Agreement
does not purport to be completed and is qualified in its entirety by reference to the Agreement, which is filed as Exhibit 10.1 to
this Current Report on Form 8-K and is incorporated herein by reference.
Section
9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.
|
Exhibit
No.
|
Document
|
Location
|
|
10.1
|
Agreement between Global WholeHealth Partners Corp and Dr. AnhDao
Vu Le
|
Filed Herewith
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Registrant)
|
|
Date:
May 14, 2021
|
By:
/s/ Charles Strongo
Charles Strongo
Chief Executive Officer
|
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
